April 26th 2025
Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be presented at ASCO 2025.
April 25th 2025
April 23rd 2025
March 10th 2025
March 7th 2025
March 6th 2025
March 5th 2025
March 31st 2025
March 3rd 2025
February 23rd 2025